Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;29(4):555-569.
doi: 10.1016/j.soc.2020.06.009. Epub 2020 Jul 29.

Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer

Boris Sepesi  1 , Tina Cascone  2 , Stephen G Chun  3 , Mehmet Altan  2 , Xiuning Le  2
Affiliations
Review

Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer

Boris Sepesi et al. Surg Oncol Clin N Am. 2020 Oct.

Abstract

Immunotherapy, targeted therapy, and adoptive T-cell therapy have been revolutionary advancements in cancer research. Some of these therapies have become the standard of care for lung cancer and replaced older treatment algorithms; some continue to be studied in clinical trials. This article discusses the current state of novel treatment options for non-small cell lung cancer patients with metastatic and locoregional disease, with focus on immunotherapy, targeted therapy, and adoptive T-cell therapy.

Keywords: Adoptive therapy; Immunotherapy; Non–small cell lung cancer; T cells; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure B. Sepesi receives consultant fees from Bristol-Myers Squibb and research funding from Rexanna Foundation. T. Cascone reports speaker’s fees from the Society for Immunotherapy of Cancer and Bristol-Myers Squibb, consulting fees MedImmune/Astra Zeneca and Bristol-Myers Squibb, and advisory role fees from EMD Serono and Bristol-Myers Squibb. S.G. Chun is on the advisory board and receives consultant fees from Astra Zeneca. M. Altan receives advisory fees from GlaxoSmithKline and Shattuck Labs and research funding from Genentech, Nektar Therapeutics, Merck, GlaxoSmithKline, Novartis, Jounce Therapeutics, Bristol-Myers Squibb, Eli Lilly, and Adaptimmune. X. Le receives consultant and advisory fees from Eli Lilly, Astra Zeneca, and EMD Serono and research funds from Eli Lilly and Boehringer Ingelheim.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sharma P., Allison J.P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–214. - PMC - PubMed
    1. Brahmer J.R., Govindan R., Anders R.A., et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) J Immunother Cancer. 2018;6(1):75. - PMC - PubMed
    1. Brahmer J., Reckamp K.L., Baas P., et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123–135. - PMC - PubMed
    1. Borghaei H., Paz-Ares L., Horn L., et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–1639. - PMC - PubMed
    1. Carbone D.P., Reck M., Paz-Ares L., et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376(25):2415–2426. - PMC - PubMed

Publication types

MeSH terms